First Trust Advisors LP Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

First Trust Advisors LP increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,300 shares of the medical equipment provider's stock after buying an additional 7,827 shares during the quarter. First Trust Advisors LP owned about 0.13% of Lantheus worth $7,810,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of LNTH. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC purchased a new position in Lantheus during the fourth quarter worth about $323,000. Focus Financial Network Inc. acquired a new stake in shares of Lantheus during the fourth quarter valued at about $292,000. Harbor Capital Advisors Inc. raised its stake in shares of Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock valued at $13,006,000 after acquiring an additional 16,466 shares during the period. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus in the 3rd quarter worth approximately $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Up 2.7 %

NASDAQ LNTH traded up $2.82 on Friday, hitting $108.74. 726,215 shares of the stock were exchanged, compared to its average volume of 937,287. Lantheus Holdings, Inc. has a fifty-two week low of $74.28 and a fifty-two week high of $126.89. The company has a 50-day moving average price of $99.90 and a 200-day moving average price of $95.15. The company has a market cap of $7.45 billion, a PE ratio of 18.09 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research analyst reports. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 over the last 90 days. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.